The Australian company active in the treatment of serious illnesses is setting down roots in Liege.
Clarity will be investing in the development of its company (Clarity Pharmaceuticals Europe SA) and its products in Belgium. Clarity will use its Belgian activities to expand in Europe and develop its networks, staff and new opportunities and collaborations. The €150,000 investment for the first year will gradually increase over the following five years. Ultimately, it should lead to the creation of 10 to 15 jobs.
This company, created in 2010 and based in Sydney, uses its radiopharmaceutical capacity to manufacture safer and more effective drugs in order to improve the quality of treatments for patients. Clarity’s technology, developed in collaboration with the Australian Nuclear Science and Technology Organisation (ANSTO) and Melbourne University, enables biopharmaceutical products to be radiomarked for therapy and displayed using PET imaging. Clarity, a leader in innovative radiopharmaceutical technology, develops targeted therapies and participates in the development of drugs in the frame of innovative treatments for companies on a global level.
Matt Harris, CEO of Clarity, indicated that it was able to find the expertise needed in Wallonia through partners such as ANMI and Delphi Genetics. Support for the company provided via the services of AWEX was also decisive in this project, which got underway in 2014 during a presentation of the advantages offered by Wallonia. The company was then put in touch with our expert Biowin, which met it on several occasions and which continues to follow the progress of the project through to the present-day. In particular, Clarity paid a visit to the incubator in Gosselies in 2014. Aid for R&D and the prompt response of the public services helped Matt Harris to decide that Wallonia was the perfect place for Clarity.
Naturally, the Minister of Economy, Jean-Claude Marcourt, is delighted with this investment which highlights the advantages offered by Wallonia: “The pharmaceutical sector and competitiveness clusters are key vehicles for the attraction of foreign investment”, he stressed.” Clarity will enrich our already well-developed biotech economic fabric even further!”.
